Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

Reports Q4 revenue $47.46M, consensus $46.05M. “2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and ...

Revenue for the fourth quarter and full year 2024 was $47.5 million and $179.0 million, respectively. The MRD business, which contributed 85% of revenue in the fourth quarter and 81% of revenue in the ...

The Supreme Court recently reiterated that further investigation can be directed even after the chargesheet has been filed ...

A bill introduced to the New York state Senate is seeking to bolster the disclosures that reverse mortgage lenders make to ...

The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry ...

Leading brokers have named ResMed Inc. (ASX: RMD) and these ASX shares as buys this week. Here's why they are bullish on ...

The Australian share market looks set to tumble on Monday. Here's what you need to know. The post 5 things to watch on the ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m ...

Explore the detailed Mount Ridley Mines Ltd balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time high of $40.17 achieved in September 2021. This is despite the fact that ...